Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072981 · ClinicalTrials.gov registry record · Phase 3
Immunotherapy Study for Surgically Resected Pancreatic Cancer
A Phase 3 study, sponsored by NewLink Genetics Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 722
- Enrollment target
NCT01072981: Completed Phase 3 study, sponsored by NewLink Genetics Corporation.
NCT01072981 is a Phase 3 study that has completed, run by NewLink Genetics Corporation. The registered enrollment target is 722 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01072981, a Phase 3 study, has completed, sponsored by NewLink Genetics Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 722 participants
- Enrollment target
Study Summary
The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL HyperAcute-Pancreas Immunotherapy
- RADIATION 5FU Chemoradiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 722 participants |
| Start Date | 2010-04 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
What the finished NCT01072981 record still lists
NCT01072981 is an interventional study that assigns participants to a tested intervention. The registered 722 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT01072981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01072981 about?
NCT01072981 is a clinical study titled "Immunotherapy Study for Surgically Resected Pancreatic Cancer". The purpose of this study is to assess overall survival after treatment with a regimen of adjuvant therapy (Gemcitabine alone or with 5-FU chemoradiation) with or without HyperAcute®-Pancreas (algenpantucel-L) immunotherapy in subjects who have undergone surgical resection.
What is the current status of trial NCT01072981?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 722 participants. The study started on 2010-04. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01072981?
The interventions under investigation include: Gemcitabine (DRUG), HyperAcute-Pancreas Immunotherapy (BIOLOGICAL), 5FU Chemoradiation (RADIATION).
Who is sponsoring clinical trial NCT01072981?
This trial is sponsored by NewLink Genetics Corporation, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01072981's enrollment target sits among peer trials
722 494th of 2000 higher than 1,507 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06116149 · 722 participants · NA
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia